SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as community members rally behind its organic growth strategy, actively avoiding the typical pump-and-dump cycles associated with other meme tokens. Investors are showing strong conviction in the project's long-term potential, frequently discussing its lack of a chart as a badge of early-stage authenticity while pushing for increased volume to drive the next leg of upward momentum.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating significant community buzz as investors debate its long-term transactional utility against Bitcoin, with many keeping a close watch on potential catalysts like institutional adoption and integration with major platforms. Traders are currently split between viewing the asset as a prime short-squeeze opportunity and maintaining a cautious stance amidst broader market volatility.

ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

ICU Medical, Inc.

ICU Medical is trending as investors evaluate its integration of recent acquisitions and the company's long-term growth potential in the infusion systems and medical device market. The community remains focused on technical turnaround potential, management performance, and the company's ability to drive hospital adoption for its specialized device products.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is seeing significant trading activity as investors react to concerns over the impact of GLP-1 weight-loss drugs on the long-term demand for dialysis services. While the market has reacted sharply to clinical trial news from the obesity drug sector, analysts and community participants are actively debating whether this sell-off represents an overreaction or a fundamental shift in the kidney care landscape.

Vanguard World Fund - Vanguard Emerging Markets Ex-China ETF

Investors are increasingly utilizing this ETF as a strategic alternative to gain exposure to emerging markets while intentionally avoiding Chinese equities. Market participants are actively debating the merits of geographical diversification in response to heightened geopolitical volatility and concerns regarding systemic stability in international markets.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community leans into its history as an original internet parody, positioning it as a cultural counter-narrative to traditional crypto assets. Discussions are dominated by debates over its long-term viability, with vocal supporters framing it as a multi-billion dollar opportunity while others dismiss the project as part of a wider trend of memetic absurdity.

ARK 21Shares Bitcoin ETF - ARK 21Shares Bitcoin ETF Beneficial Interest

ARK 21Shares Bitcoin ETF

Investors are closely monitoring Bitcoin ETFs like ARKB, IBIT, and FBTC as sustained institutional demand and significant daily inflows continue to drive market sentiment despite recent price volatility. The broader community remains focused on the potential impact of the upcoming halving and the long-term role of Bitcoin as a strategic asset amidst ongoing macroeconomic shifts.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing heightened volatility and intense social debate, with bulls pointing to potential legislative catalysts like the Clarity Act and accumulation trends, while bears express deep skepticism, citing long-term price underperformance and dismissing the project as a cycle-dependent scam.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is facing increased volatility and investor scrutiny as shareholders navigate the impact of conservative forward revenue guidance and the upcoming transition in reimbursement for DefenCath. While the community remains divided over management's communication and strategy, discussion is heavily focused on potential legislative catalysts like the Kidney Care Access Protection Act and the anticipated readout of Phase 3 trial data for Rezzayo.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently trending as investors debate the potential for a renewed upward leg, with many pointing to the recent Canary Capital ETF filing as a major catalyst for institutional legitimacy. The community remains divided between those viewing the current volatility as a prime accumulation zone and others cautioning against meme coin cyclicality, while overall sentiment remains heavily tethered to broader Bitcoin and Ethereum market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire REHOVOT, Israel, March 26, 2026 REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlantBiotechnologies (Nasdaq...

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement PR Newswire REHOVOT...

CollPlant Biotechnologies Launches Redesigned Corporate Website

CollPlant Biotechnologies Launches Redesigned Corporate Website CollPlant Biotechnologies Launches Redesigned Corporate Website PR Newswire REHOVOT, Israel, March 18, 2026 REHOVOT, Israel, March 18...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS PR Newswire REHOVOT, Israel, March 11, 2026...

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal...

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex PR Newswire...

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments PR Newswire REHOVOT, Israel, Feb. 17, 2026...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PR Newswire REHOVOT, Israel, Feb. 5, 2026...

<ul class="summary-bullets"><li>The workforce reduction plan is expected to impact 25% of the company’s workforce.</li><li>The company’s adjusted net loss per share in Q3 came in at $0.25, but analysts, on average, expected earnings of $0.15 per share.</li><li>The company reported revenue of $77,000 for the three months ended September.</li></ul>Shares of CollPlant Biotechnologies (CLGN) slumped 14% on Wednesday morning after the company reported third-quarter earnings below Wall Street expectations.The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-2025-third-quarter-financial-results-and-provides-corporate-update-302626666.html">reported</a> revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.Adjusted net loss per share came in at $0.25, lower than the $0.33 loss reported in the corresponding quarter of 2024. Still, analysts, on average, were expecting the company to report earnings of $0.15 per share.<h2 class="st-heading-2">Cost-Cutting Efforts And Layoffs</h2>The company said it has initiated a cost-cutting and workforce-reduction plan, which is expected to result in about a 25% cut in its workforce."In 2026, CollPlant will prioritize its collaboration with AbbVie and continue advancing its own dermal filler product candidate… In parallel, we plan to actively seek a strategic partner to collaborate with us on the continued development of our novel regenerative breast implant product candidate," Collplant CEO Yehiel Tal said.CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The company's products are based on its recombinant human collagen. The company entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, in 2021."We remain highly encouraged by the additional results emerging from the preclinical studies of our commercial-size regenerative breast implants, as well as from the ongoing evaluations of our photocurable dermal filler program,” Tal added. The photocurable derma filler program is now in the final stages of preclinical testing, and the company is now preparing for the initial clinical studies, IT said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/CLGN">CLGN stock</a> stayed within the ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.CLGN stock is down 44% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a smartphone displays the logo of CollPlant Biotechnologies Ltd., an Israel-based regenerative and aesthetic medicine company, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

CLGN Stock Crashed 14% Today – Disappointing Earnings, Workforce Reduction Plan Draws Investor Attention

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI. 

Equity

The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI. 


COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE...

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

CLGN
CollPlant Biotechnologies Ltd - Ordinary Shares New

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLGN News

CLGNCollPlant Biotechnologies Ltd - Ordinary Shares New